P.O. Box 50030 London, ON N6A 6H8 info@rett.ca (519) 474-6877

Tag: Acadia

Priority Review by Health Canada

Just announced at the 2024 Ascend Rett National Conference, Health Canada has accepted regulatory applications from Acadia Pharmaceuticals for DayBue (Trofinetide), but has also been accepted for a priority review by Health Canada. We were honored to be… Read More

Health Canada Accepts a New Drug Submission 

Health Canada Accepts New Drug Submission for Trofinetide Acadia Pharmaceuticals is pleased to share that Health Canada has accepted their New Drug Submission (NDS) of trofinetide for the treatment of Rett Syndrome. Moreover, the treatment has been granted Priority Review to… Read More

DayBue Announcement

Acadia Pharmaceuticals Announces DAYBUE™ (trofinetide) is Now Available for the Treatment of Rett Syndrome  — Commercial launch of DAYBUE offers Rett syndrome community the first and only approved therapy for Rett syndrome, a rare, neurodevelopmental disorder, which affects 6,000… Read More